natgillin/translations-raw huggingface dataset:
Within the designated system organ classes, the adverse drug reactions are listed under headings of frequency and using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Neželeni učinki za navedene organske sisteme so podani po posameznih kategorijah pogostnosti v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Within the dose range of 0.003-0.02 mg/kg (or approximately 0.18-1.2 mg) in healthy subjects, clearance, terminal half-life or volume of distribution do not appear dependent upon the dose.
V razponu odmerka 0,003-0,02 mg/kg (ali približno 0,18-1,2 mg) pri zdravih osebah očistek, končna razpolovna doba ali volumen porazdelitve niso odvisni od odmerka.
Within the following table, adverse reactions are ranked under the MedDRA frequency classification:
V spodnji tabeli so neželeni učinki razvrščeni v skladu z navedbo pogostnosti po MedDRA:
Within the four clinical studies discussed in this PUSA, ‘pallor’ or ‘over-whitening of the skin’ has been reported.
V štirih kliničnih študijah, obravnavanih v tem poročilu PSUSA, so poročali o „bledici” oziroma
Within the highest quartile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.74 (95% CI, 0.49 - 1.12).
V najvišji kvartili glede na sredino je bilo razmerje tveganja z rivaroksabanom v primerjavi z varfarinom 0,74 (95 % IZ, 0,49 do 1,12).
Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).
V najvišji tercili glede na sredino je bilo razmerje tveganja z rivaroksabanom v primerjavi z varfarinom 0,642 (95 % IZ: 0,277 - 1,484).
Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).
V najvišji tercili glede na sredino je bilo razmerje tveganja z rivaroksabanom v primerjavi z varfarinom 0,69 (95 % IZ: 0,35 do 1,35).
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
V okviru razvrstitve po organskih sistemih so neželeni učinki razvrščeni po naslednjih kategorijah pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10), and uncommon (≥ 1/1,000 to
Neželeni učinki so navedeni po organskih sistemih, z naslednjimi kategorijami pogostnosti: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10) in občasni (od
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥ 1/1,000 to
Neželeni učinki so navedeni po organskih sistemih, z naslednjimi kategorijami pogostnosti: zelo pogosti (≥1/10), pogosti (od ≥1/100 do <1/10), občasni (od ≥1/1.000 do <1/100), redki (od ≥ 1/10.000 do
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to
V okviru organskih sistemov so neželeni učinki navedeni z naslednjimi kategorijami pogostnosti: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10), občasni (od ≥ 1/1.000 do < 1/100), redki (od
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000); not known.
Neželeni učinki so navedeni po organskih sistemih, z naslednjimi kategorijami pogostnosti: zelo pogosti (≥1/10), pogosti (od ≥1/100 do <1/10), občasni (od ≥1/1.000 do <1/100), redki (od ≥ 1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana.
Within the planned post-authorisaton sub-study of the THAOS registry the MAH shall evaluate in non-V30M patients the effects of Vyndaqel on disease progression and its long term safety as detailed in a CHMP agreed protocol, and shall provide yearly updates on the collected data within the annual re-assessment.
V okviru načrtovane podštudije registra THAOS po pridobitvi dovoljenja za promet z zdravilom, bo imetnik dovoljenja za promet z zdravilom pri bolnikih z ne-V30M ovrednotil učinke zdravila Vyndaqel na napredovanje bolezni in varnost njegove dolgotrajne uporabe, kot je to podrobno predstavljeno v protokolu, dogovorjenem s CHMP, in bo letno poskrbel za posodobitev zbranih podatkov v okviru vsakoletne ponovne ocene.
Within the prescriber guide there will be a check-list to remind prescribers of the contraindications, warnings and precautions prior to prescribing and to support the regular monitoring of cardiovascular risk.
Navodila za zdravnika vsebujejo tudi seznam za preverjanje, ki bo zdravnika spomnil na kontraindikacije, opozorila in previdnostne ukrepe preden bo predpisal zdravilo, in zagotovil redno spremljanje tveganja za srčno-žilne dogodke.
Within the RA, PsA, AS, and nr-Axial SpA pivotal trials, one patient in an RA trial with pre-existing liver abnormalities and confounding medicinal products treated with golimumab developed non-infectious fatal hepatitis with jaundice.
V okviru ključnih preskušanj pri bolnikih z RA, PsA, AS in nr-aksialnim SpA se je pri enem bolniku (v preskušanju RA) z obstoječimi motnjami jeter, ki je med zdravljenjem z golimumabom prejemal tudi druga zdravila, ki so zameglila stanje, pojavil smrtni neinfekcijski hepatitis z zlatenico.
Within the system organ class, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10).
V okviru vsakega organskega sistema so neželeni učinki navedeni po pogostnosti, ki je opredeljena z naslednjima kategorijama: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10).
Within the system organ classes they are listed under the following headings: Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to
Navedeni so po organskih sistemih z naslednjimi opisi pogostnosti: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1000 do
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Neželeni učinki so navedeni po organskih sistemih in razvrščeni po pogostnosti (pričakovano število bolnikov, ki bodo doživeli neželen učinek) v naslednje skupine: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000).
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000); very rare (< 1/10,000).
Neželeni učinki so navedeni po organskih sistemih in razvrščeni po pogostosti (pričakovano število bolnikov, ki bodo doživeli neželen učinek) v naslednje skupine: zelo pogosti (≥ 1/10), pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1000, < 1/100), redki (≥ 1/10.000, < 1/1000), zelo redki (< 1/10.000).
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); not known (cannot be estimated from the available data).
Znotraj organskih sistemov so neželeni učinki navedeni po pogostnosti (število bolnikov, pri katerih se pričakuje pojav neželenega učinka), z uporabo naslednjih kategorij: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to
Neželeni učinki so znotraj organskih sistemov razvrščeni po pogostnosti v naslednje skupine: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do
Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to
Neželeni učinki so znotraj organskih sistemov razvrščeni po pogostnosti v naslednje skupine: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do ≤ 1/100), redki (≥ 1/10.000 do
Within the system organ classes, undesirable effects are listed under headings of frequency, using the following categories: very common (1/10); common (1/100 to <1/10); uncommon (1/1,000 to
Neželeni učinki so znotraj organskih sistemov razvrščeni po pogostnosti v naslednje skupine: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do ≤1/100), redki (≥1/10.000 do ≤1/1.000), zelo redki (≤1/10.000), z neznano pogostnostjo (iz podatkov, ki so na voljo določitev ni mogoča).
Within these trials, 1,221 subjects received a daily dose of 4 mg/kg, of whom 1,108 were patients and 113 were healthy volunteers; 460 subjects received a daily dose of 6 mg/kg, of whom 304 were patients and 156 were healthy volunteers.
1.221 oseb prejemalo dnevni odmerek 4 mg/kg, od teh je bilo 1.108 bolnikov, 113 pa zdravih prostovoljcev; 460 oseb je prejemalo dnevni odmerek 6 mg/kg, od teh so bili 304 bolniki, 156 pa je bilo zdravih prostovoljcev.
Within this population, 104 HIV-1 infected paediatric subjects weighing at least 25 kg received abacavir and lamivudine as Kivexa once daily.
Znotraj te populacije so 104 s HIV-1 okuženi pediatrični preiskovanci, ki so tehtali vsaj 25 kg, prejemali abakavir in lamivudin v obliki zdravila Kivexa enkrat dnevno.
within two hours of infusion
infundiranjem ali v roku dveh ur po infundiranju
Within two weeks of stopping Revolade, your blood platelet count will usually drop back down to what it was before starting Revolade.
V dveh tednih po prekinitvi zdravljenja z zdravilom Revolade se število trombocitov običajno zmanjša na vrednosti pred začetkom zdravljenja z zdravilom Revolade.
Within ZEST, immune responses to vaccination were evaluated in a random 10% subcohort (n=1,136 for ZOSTAVAX and n=1,133 for placebo) of the subjects enrolled in the ZEST.
V študiji ZEST so imunski odziv na cepljenje vrednotili pri naključni 10 % subkohorti (n=1.136 za cepivo ZOSTAVAX, n=1.133 za placebo) oseb, vključenih v ZEST.
Within-group change
prememba znotraj skupine
Within-group change
sprememba znotraj skupine
Within-subject variability of the time action profile of Levemir and NPH insulin
Spremenljivost časovnega poteka delovanja zdravila Levemir in insulina NPH
without
(odprta)
without
brez
without
kandesartan
without
ksiltenofovirat
without
m ali brez
without
Mehanizem:
without
Ni raziskan.
Without a loading dose, it is estimated that attainment ofsteady-state plasma concentrations would require nearly two months of dosing.
Ocenjujejo, da bi zdravilo brez udarnega odmerka doseglo koncentracijo v stanju dinamičnega ravnotežja v plazmi šele po skoraj dvomesečnem jemanju.
Without affecting overall survival time (docetaxel 15 months vs. doxorubicin 14 months, p = 0.38) or time to progression (docetaxel 27 weeks vs. doxorubicin 23 weeks, p = 0.54), docetaxel increased response rate (52% vs.
Docetaksel ni vplival na celotni čas preživetja (docetaksel 15 mesecev, doksorubicin 14 mesecev, p = 0,38) niti na čas do napredovanja (docetaksel 27 tednov, doksorubicin
Without affecting the primary endpoint, overall response rate (32% vs 25%, p=0.10), docetaxel prolonged median time to progression (24.6 weeks vs 15.6 weeks; p<0.01) and median survival (15.3 months vs 12.7 months; p=0.03).
Docetaksel ni vplival na primarno končno točko, celotni delež odziva (32 % v primerjavi s 25 %, p = 0,10), podaljšal pa je srednji čas do napredovanja bolezni (24,6 tedna v primerjavi s 15,6 tedna, p < 0,01) in srednje trajanje preživetja (15,3 meseca v primerjavi z 12,7 meseca, p = 0,03).
Without an accelerated elimination procedure, clearance of teriflunomide from plasma can take from several months up to 2 years.
Brez pospešenega postopka izločanja lahko očistek teriflunomida iz plazme traja od več mesecev do 2 let.
without any dose
brez prilagoditve odmerkov,
Without baseline NS5A RAVs
Brez izhodiščnih RAV NS5A
WITHOUT BLUE BOX
obloženih tablet) - BREZ "BLUE BOX" PODATKOV
without cirrhosis
brez nje), ali preiskovance, ki se niso odzvali
without cirrhosis with cirrhosis
brez ciroze s cirozo
Without crushing it, the tablet should be dropped in half a glass of drinking water.
Tableto dajte v pol kozarca vode za pitje, ne da bi jo zdrobili.
without dasabuvir
dasabuvirja
without dasabuvir
dasabuvirjem ali brez
without dasabuvir is
feksofenadina z
without dasabuvir.
potrebna.
without dilution, after transfer to an infusion container using an appropriate sterile syringe; or
brez redčenja, po prenosu v infuzijski vsebnik z ustrezno sterilno injekcijsko brizgo ali
without dilution, after transfer to an infusion container using an appropriate sterile syringe; or
brez redčenja, po prenosu v infuzijski vsebnik z ustrezno sterilno injekcijsko brizgo, ali
without dilution, after transfer to an infusion container using an appropriate sterile syringe; or after diluting to concentrations as low as 1 mg/mL.
brez redčenja, po prenosu v infuzijski vsebnik z ustrezno sterilno injekcijsko brizgo, ali po redčenju do najmanjše koncentracije 1 mg/ml.
without dilution, after transfer to an infusion container using an appropriate sterile syringe; or after diluting to concentrations as low as 1 mg/mL.
brez redčenja, po prenosu v infuzijski vsebnik z ustrezno sterilno injekcijsko brizgo, ali po redčenju do najnižje koncentracije 1 mg/ml.
without dose adjustment.
brez prilagajanja odmerka.
without dose adjustment.
odmerka ni potrebna.
without dose adjustment.
odmerka.
without dose adjustments.
brez prilagoditve odmerka.
without dose adjustments; however,
odmerkov, vendar je zaradi zvečane
without enough skin or blood supply at the fracture site;
osebe, pri katerih mesto zloma ni ustrezno pokrito s kožo ali dovolj prekrvavljeno;
Without hepatitis B vaccination at birth
brez cepljenja proti hepatitisu B ob rojstvu
Without idarucizumab, the mortality in the anticoagulated group was 100 %.
Brez idarucizumaba je smrtnost v antikoagulirani skupini znašala 100 %.
Without inhibitor
brez zaviralca
without Q80K
brez Q80K
without ritonavir, in combination with Viekirax with dasabuvir.
ritonavirja, v kombinaciji z zdravilom Viekirax in dasabuvirjem.
Without Tenofovir disoproxil fumarate
Brez dizoproksiltenofovirat fumarata
Without the ability to generate energy, the bacteria die and the patient’s condition can start to improve.
Če bakterije ne morejo več pridobivati energije, odmrejo, bolnikovo stanje pa se začne izboljševati.
WITHOUT THE BLUE BOX
5) – BREZ MODRE ŠKATLE
Without touching the rubber top the vial should be swirled vigorously until the content is completely mixed.
Močno vrtite vialo, dokler ni vsebina povsem premešana, pri tem pa se ne dotikajte gumijastega vrha.
Without touching the sticky surface, firmly press the patch, adhesive face down, onto the part of the abdomen, hips or buttocks you have selected for application.
Brez da se dotaknete lepljive površine, nežno stisnite obliž z lepljivim delom navzdol na del trebuha, bokov ali zadnjice, kamor želite obliž nalepiti.
WITHOUT twisting the knob, ROTATE the pen every few taps.
Peresnik vsakih nekaj udarcev OBRNITE, NE DA BI pri tem zasukali gumb.
wk 12
12. ted en
wk 24a
24. ted ena
wollen abdomen
otekanje trebuha
wollen and usually itchy patches of skin or mucous membranes (urticaria)
otekli in običajno srbeči predeli kože ali sluznice (urtikarija)
wollen and usually itchy patches of skin or mucous membranes (urticaria),
običajno srbeči in otekli predeli na koži ali sluznicah (urtikarija)
wollen eyelids, lips or tongue
oteklino očesnih vek, ustnic ali jezika,
wollen eyes, lips, hands or feet
otečene oči, ustnice, dlani ali stopala;
wollen face
oteklina obraza
wollen face various types of cancers including blood, lymph and skin cancers
otečen obraz različne vrste raka, vključno s krvnim, limfnim in kožnim rakom
wollen face, hands or feet
otekanje obraza, rok ali nog,
wollen face, hands or feet
otekanje obraza, rok ali nog.
wollen face, hands, feet (angioedema)
otečen obraz, roke, stopala (angioedem)
wollen face, tongue, or throat
otekanje obraza, jezika ali grla;
wollen glands
otečene žleze,
wollen glands (lymph nodes)
otečene žleze (bezgavke),
wollen glands in the neck, armpit or groin
otekle bezgavke na vratu, pod pazduho ali v dimljah,
wollen glands in the neck, armpit or groin (lymphadenopathy)
oteklost bezgavk na vratu, v pazduhah ali dimljah (limfadenopatija),
wollen glands in the neck, armpit or groin (lymphadenopathy) flu-like symptoms, such as high temperature, sore throat, runny nose, cough and chills
otekle bezgavke na vratu, v pazduhah ali dimljah (limfadenopatija), gripi podobni simptomi, npr. zvišana telesna temperatura, vnetje žrela, izcedek iz nosu, kašelj in mrzlica.
wollen glands in the neck, armpit or groin fainting sometimes accompanied by shaking or stiffness.
povečane bezgavke na vratu, pod pazduho ali v dimljah, omedlevica, ki jo včasih spremlja tresenje ali togost.
wollen glands, blood disorders (reduction in the number of blood cells, which can make infection more likely and can make you look pale, feel tired and feverish, and bruise more easily)
otekle bezgavke, bolezni krvi (zmanjšanje števila krvničk, zaradi katerega ste dovzetnejši za okužbe, ste bledi, utrujeni in vročični ter bolj nagnjeni k nastanku modric);
wollen glands, blood disorders (reduction in the number of blood cells, which can make infection more likely and can make you look pale, feel tired and feverish, and bruise more easily). decreased sweating, overheating.
otekle bezgavke, bolezni krvi (zmanjšanje števila krvničk, zaradi katerega se lažje okužite, ste bledi, utrujeni in vročični in vam brez omembe vrednega vzroka nastajajo modrice); zmanjšano znojenje, pregrevanje telesa.
wollen hands, ankles and feet (oedema)
otekanje rok, gležnjev in stopal (edemi)
wollen hands, ankles and feet. tiredness.
otekanje rok, gležnjev in stopal utrujenost
wollen legs
otekle noge,
wollen legs or feet
otekanje nog in stopal,
wollen lymph nodes
otekli limfni vozli
wollen lymph nodes,
otekle bezgavke
wollen or enlarged glands near the elbow or under the arm swelling in the hand or arm
otečene ali povečane bezgavke blizu komolca ali pod pazduho; oteklina roke ali cele zgornje okončine.
wollen or flushed face feeling tired, dizzy or light-headed.
otečen ali zardel obraz; utrujenost, omotica ali vrtoglavost.
wollen or painful tongue
otekel in boleč jezik
wollen stomach
napihnjenost želodca,
wollen tongue,
ileus, otečen
wollen tongue, gastroenteritis, dysphagia, flatulence
otečen jezik, gastroenteritis, disfagija, flatulenca
wollen tongue, stomach or intestinal infection, difficulty swallowing, excessive passing of gas or wind increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, increased liver enzymes in your blood
otečen jezik, okužba želodca ali črevesja, oteženo požiranje, prekomerno izločanje plina in vetrov zvišana koncentracija GGT (jetrni encim, ki ga imenujemo gama glutamil transferaza) v krvi, zvišana koncentracija jetrnih encimov v krvi
wollen veins in the rectum or anus (haemorrhoids), pain in the anus or rectum; skin rash and itching of the skin.
otekle vene v danki ali zadnjiku (hemoroidi), bolečine v danki ali zadnjiku, kožni izpuščaj in srbenje kože.
wollen, red and blistering skin around where the drip was given
otečena, rdeča in mehurjasta koža okrog mesta infundiranja;
Woman of childbearing potential/Contraception in the males and females
Ženske v rodni dobi/kontracepcija pri moških in ženskah
Woman population ≥ 27 years of age
Populacija žensk, starih ≥ 27 let
Women and their partners should therefore also use a barrier method of contraception such as condoms.
Ženske in njihovi partnerji bi morali zato sočasno uporabljati pregradno metodo kontracepcije, kot so kondomi.
Women appear to be at higher risk than men of developing rash, whether receiving nevirapine or non- nevirapine containing therapy.
Kaže, da je tveganje pojava izpuščaja pri ženskah večje kot pri moških ne glede na to, ali prejemajo zdravljenje, ki vključuje nevirapin, ali takšno, ki ga ne vsebuje.
Women given Cancidas should not breast-feed.
Ženske, ki uporabljajo zdravilo Cancidas, ne smejo dojiti.
Women given Caspofungin Accord should not breast-feed.
Ženske, ki uporabljajo zdravilo Kaspofungin Accord, ne smejo dojiti.
Women have a three fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8 % versus 2.2 %), and treatment-naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy are at higher risk for symptomatic hepatic events with nevirapine.
Pri ženskah je tveganje simptomatskih jetrnih dogodkov ob uporabi nevirapina, ki jih pogosto spremlja izpuščaj, trikrat večje kot pri moških (5,8 % proti 2,2 %), pri prvič zdravljenih bolnikih obeh spolov, ki imajo v plazmi izmerljivo raven HIV- 1RNA in pri bolnikih z večjim številom celic CD4 je v uvajalnem obdobju zdravljenja z nevirapinom povečano tveganje simptomatskih jetrnih dogodkov.
Women having Myocet should not breast-feed.
Ženske, ki jemljejo zdravilo Myocet, ne smejo dojiti.
women infected with hepatitis B or C
ženskah, pri okužbi z virusom hepatitisa B ali C,
Women may experience a delay in conception following discontinuation of EVRA.
Po prenehanju uporabe obliža EVRA lahko pri ženskah pride do kasnejše zanositve.
Women must not breastfeed during treatment with Lynparza and for at least one month after treatment.
Bolnice ne smejo dojiti med zdravljenjem z zdravilom Lynparza in vsaj en mesec po zdravljenju.
Women must not get pregnant while taking Eviplera.
Ženske ne smejo zanositi, medtem ko se zdravijo z zdravilom Eviplera.
Women must not get pregnant while taking Stribild.
Ženske ne smejo zanositi, medtem ko se zdravijo z zdravilom Stribild.
Women must not get pregnant while taking Vitekta.
Ženske ne smejo zanositi, medtem ko se zdravijo z zdravilom Vitekta.
Women must use effective contraception during treatment with ALIMTA.
Med zdravljenjem z zdravilom ALIMTA morajo ženske uporabljati učinkovito metodo kontracepcije.
Women must use effective contraception during treatment with Pemetrexed medac.
Med zdravljenjem z zdravilom Pemetreksed medac morajo ženske uporabljati učinkovito metodo kontracepcije.
Women must use effective contraception during treatment.
Ženske morajo uporabljati učinkovito kontracepcijo v času zdravljenja.
Women of child bearing potential and Pregnancy
Ženske v rodni dobi in nosečnost
Women of child bearing potential should avoid becoming pregnant during treatment with rivaroxaban.
Ženske v rodni dobi naj se med zdravljenjem z zdravilom Xarelto izogibajo zanositvi.
Women of child bearing potential should avoid becoming pregnant during treatment with varenicline.
Ženske v rodni dobi se morajo med zdravljenjem z vareniklinom izogibati zanositvi.
Women of child bearing potential/Contraception in males and females
Ženske v rodni dobi/Kontracepcija pri moških in ženskah